RxDoctor Payments DataLook up a doctor →

Charlotte Ingwersen, MD

Family Medicine · Shepherdsville, KYNPI 1003810987

Payments from drug & device makers

$11,364in general payments, 2019–2025

Across 831 payments — averaging $13.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • AstraZeneca$750
  • Lilly USA, LLC$714
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$11,341100%
  • Education$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,364 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$154,938
Medicare patients
206
Services billed
5,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide117$146,716
OzempicSemaglutide34$41,121
FarxigaDapagliflozin Propanediol24$32,489
Repatha SureclickEvolocumab26$27,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$25,747
JardianceEmpagliflozin24$25,594
EliquisApixaban18$23,526
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$18,896
XareltoRivaroxaban13$17,199
Xigduo XrDapaglifloz Propaned/Metformin18$15,981
LinzessLinaclotide18$12,936
Repatha SyringeEvolocumab16$11,513
Combivent RespimatIpratropium/Albuterol Sulfate14$10,100
SymbicortBudesonide/Formoterol Fumarate18$7,461
Praluent PenAlirocumab11$5,049

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Humalog$714$150,835131 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Combivent Respimat$347$54,59057 claims
Novo NordiskOzempic, Novolog$1,121$43,81545 claims
AstraZenecaFarxiga, Symbicort$750$39,95042 claims
GSKTrelegy Ellipta$274$25,74733 claims
PfizerEliquis$1,030$23,52618 claims
Johnson & JohnsonXarelto$75$17,19913 claims
AbbVieLinzess$1,627$12,93618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →